Clinical trials: Bone and Joint Infection
Diarrheal Disease, Infectious, Gastrointestinal Disease
Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy Adults
This is a Phase 1 dose escalating study to assess the safety, tolerability, and immunogenicity of ShigETEC, a live, attenuated Shigella/ETEC combination vaccine given orally to healthy European adults 18 to 45 years of age.
- Conditions
- Diarrheal Disease, Infectious, Gastrointestinal Disease, Reactive Arthritis
- Trial name
- NCT05409196
- Testing
- ShigETEC live, attenuated, oral vaccine
- Where
- Hungary
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Eveliqure Biotechnologies GmbH
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.
- Conditions
- Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
- Trial name
- BE CARING (NCT06888193)
- Testing
- Bimekizumab
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 20 people
- Sponsor
- UCB Biopharma SRL
Osteomyelitis
Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci
This is a research study designed to look at the efficacy and safety of daptomycin given at a dose of 6 mg/kg or 8 mg/kg in subjects being treated for prosthetic hip or knee infections caused by Staphylococci.
- Trial name
- NCT00428844
- Testing
- daptomycin, vancomycin, teicoplanin
- Where
- 26 sites in United States, Russia and 1 more
- Volunteers
- 75 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Arthritis, Traumatic Arthritis
Hydrogel Coating to Reduce Post-surgical Infection After Joint Arthroplasty
The goal of this randomized, controlled, monocentric, single-blind, 2-arm, feasibility clinical investigation is to evaluate the safety of MectaShield hydrogel coating and to capture its preliminary clinical performance in the…
- Conditions
- Arthritis, Traumatic Arthritis, Avascular Necrosis
- Trial name
- NCT05679232
- Testing
- Hydrogel coating, Control
- Where
- Austria
- Volunteers
- 56 people
- Sponsor
- Medacta International SA
Rheumatoid Arthritis, Ankylosing Spondylitis
Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab
The purpose of this study is to assess whether or not adalimumab (Humira®) can influence pain medication in participants with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) with or without…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01273519
- Where
- 15 sites in Austria
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- AbbVie (prior sponsor, Abbott)
Bone and Joint Prosthetic Infections
BJI Inoplex 2 : Test for Diagnosis of Prosthetic Infections
A national, prospective, open-label, non-interventional, multicentre, controlled study designed to evaluate a diagnostic method in patients undergoing hip, knee or shoulder prosthetic removal regardless of whether or not…
- Trial name
- NCT02222792
- Where
- 2 sites in France
- Volunteers
- 540 people
- Sponsor
- Diaxonhit
Spondylitis, Ankylosing
A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis
The purpose of this study is to evaluate the safety and efficacy of subcutaneous injections (under the skin) of golimumab for the treatment of active ankylosing spondylitis [AS(arthritis of the spine)].
- Trial name
- NCT00265083
- Testing
- golimumab
- Where
- 39 sites in United States, Belgium and 7 more
- Volunteers
- 356 people
- Sponsor
- Centocor, Inc.
Osteo Arthritis Shoulders, Osteonecrosis
Exactech Shoulder Post Market Clinical Follow-up Study
The objective of this study is to collect and evaluate long-term clinical and radiographic outcomes data in order to better understand the safety and performance of the shoulder arthroplasty over time.
- Conditions
- Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy
- Trial name
- NCT05603728
- Where
- 40 sites in United States, Canada and 4 more
- Volunteers
- 20,000 people
- Sponsor
- Exactech
Psoriatic Arthritis
Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis
The purpose of this study was to demonstrate efficacy including effect on inhibition of progression of structural damage, safety and tolerability up to 2 years with primary focus at Week 16 (week 24 for structural damage), to…
- Trial name
- FUTURE5 (NCT02404350)
- Testing
- Secukinumab
- Where
- 172 sites in United States, Argentina and 26 more
- Volunteers
- 997 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Rheumatoid; Spondylitis, Ankylosing; Arthritis, Psoriatic; Colitis, Ulcerative
Tracking Biologics Along the Silk Road
The objective of this study is to explore and describe the disease characteristics, treatment and outcomes of participants with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's Disease or ulcerative…
- Trial name
- HARIR (NCT03006198)
- Where
- 8 sites in Algeria, Egypt and 3 more
- Volunteers
- 140 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Musculoskeletal Diseases
A Study of Incidence of Musculoskeletal Disorders in Children Who Have Received Levofloxacin or a Standard Non-Fluoroquinolone Therapy for Acute Bacterial Infection
The purpose of this study is to assess the long-term safety of levofloxacin administered to children as therapy for acute bacterial infection.
- Trial name
- NCT00210639
- Testing
- No intervention
- Where
- 62 sites in United States, Argentina and 6 more
- Volunteers
- 2,233 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Rheumatoid Arthritis, Psoriatic Arthritis
A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
The purpose of this study is to assess the safety and effectiveness of golimumab for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis among Filipino patients.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT01692457
- Testing
- No intervention
- Sponsor
- Janssen Pharmaceutica
Rheumatoid Arthritis, Ankylosing Spondylitis
Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
The purpose of this non-interventional, multicenter, post-marketing observational study (PMOS) was to assess rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn's…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Crohn´s Disease
- Trial name
- Adherence (NCT01768858)
- Testing
- Adalimumab
- Volunteers
- 96 people
- Sponsor
- AbbVie
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Psoriasis
Post-Marketing Surveillance Study of OTEZLA
To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica 1.
- Trial name
- NCT03284879
- Where
- Japan
- Volunteers
- 1,086 people
- Sponsor
- Amgen